Tisagenlecleucel versus blinatumomab or inotuzumab for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A randomized, open-label, multicenter, phase III trial (OBERON).

  • Wei, Andrew (Primary Chief Investigator (PCI))
  • Kennedy, Nola (Project Manager)

Project: Research

StatusActive
Effective start/end date28/03/1931/12/24

Keywords

  • Malignant Haematology
  • Acute lymphoblastic leukaemia (ALL)
  • Clinical trial
  • Malignant Haematology
  • Acute lymphoblastic leukaemia (ALL)
  • Clinical trial
  • Malignant Haematology
  • Acute lymphoblastic leukaemia (ALL)
  • Clinical trial